Vimarsana
Biggest News Aggregation in the World

Ntla 2001 News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Ntla 2001. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Ntla 2001 Today - Breaking & Trending Today

Bridgebio seeks Japan approval of acoramidis for rare heart disease - Vimarsana News

Bridgebio seeks Japan approval of acoramidis for rare heart disease

Published: February 6, 2024

Armed with strong phase III safety data in Japanese patients, Palo Alto, Calif.-based Bridgebio Pharma Inc. is planning to file for Japan approval of its investigational drug acoramidis for a rare heart disorder.

Source: bioworld.com
Related Topics:
Pharma IncPalo AltoBridgebio PharmaBridgebio Pharma IncAsia PacificAttr CmTransthyretin Meditated Amyloid CardiomyopathyPfizer IncAttribute CmPhase IiiSafety DataAlnylam Pharmaceuticals IncIonis Pharmaceuticals IncAstrazeneca PlcIntellia Therapeutics IncNtla 2001Transthyretin Amyloid CardiomyopathyBioworld Asia
Intellia Therapeutics: FDA Allows To Begin Phase 3 Trial Of NTLA-2001 - Vimarsana News

Intellia Therapeutics: FDA Allows To Begin Phase 3 Trial Of NTLA-2001

Published: October 18, 2023

Intellia Therapeutics, Inc. (NTLA) announced the FDA has cleared the company's Investigational New Drug application for NTLA-2001 for the treatment of transthyretin amyloidosis with cardiomyopathy.

Source: rttnews.com
Related Topics:
Inspection ServiceUs Department Of Agriculture Food SafetyMorgan StanleyPhu Huong Food CoCalifornia Based Phu Huong FoodFood SafetyIntellia TherapeuticsNtla 2001